The analysis of cfDNA mutations has already been introduced in the guidelines of non-small cell lung cancer management where secondary EGFR mutation T790M is being followed for early detection of acquired resistance to first-line EGFR-tyrosine-kinase-inhibitors [11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.